LEADER 05353nam 22006735 450 001 9910298417803321 005 20200705112315.0 010 $a1-4939-7193-X 024 7 $a10.1007/978-1-4939-7193-0 035 $a(CKB)4100000003359124 035 $a(DE-He213)978-1-4939-7193-0 035 $a(MiAaPQ)EBC6314786 035 $a(MiAaPQ)EBC5576267 035 $a(Au-PeEL)EBL5576267 035 $a(OCoLC)1031374838 035 $a(PPN)22669433X 035 $a(EXLCZ)994100000003359124 100 $a20180411d2018 u| 0 101 0 $aeng 135 $aurnn#008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aPancreatic Cancer /$fedited by John P. Neoptolemos, Raul Urrutia, James L. Abbruzzese, Markus W. Büchler 205 $a2nd ed. 2018. 210 1$aNew York, NY :$cSpringer New York :$cImprint: Springer,$d2018. 215 $a1 online resource (244 illus., 177 illus. in color. eReference.) 225 1 $aSpringer reference 300 $a"With 244 figures and 93 tables." 311 $a1-4939-7192-1 311 $a1-4939-7191-3 320 $aIncludes bibliographical references and index. 327 $aSection: The Nature of Pancreatic Cancer -- Cell Cycle Machinery and Its Alterations in Pancreatic Cancer -- Animal modelling of Pancreatitis-to-Cancer Progression -- Stromal Inflammation in Pancreatic Cancer: Mechanisms and Translational Applications -- Familial Pancreatic Cancer -- Section: Clinical Management of Pancreatic Cancer -- Therapeutic Endoscopy in the Management of Pancreatic Cancer -- Controversies in Pathology Reporting and Staging -- Staging and Postoperative Outcomes Using the International Study Group of Pancreatic Surgery (ISGPS) Classifications -- Borderline Respectable Pancreatic Cancer -- New Japanese Classification of Pancreatic Cancer -- Arterial Resection in Pancreatic Cancer -- Treatment of Recurrent Pancreatic Cancer After Surgery -- Neoadjuvant Chemotherapy in Pancreatic Cancer -- Differential Therapy Based on Tumor Heterogeneity in Pancreatic Cancer -- Neoadjuvant Chemoradiation for Operable Pancreatic Cancer: the Importance of Local Disease Control -- Section: New Directions -- Development of Novel Therapeutic Response Biomarkers -- Clinical Applications of Genomics and Proteomics in Pancreatic Cancer -- Approaching Pancreatic Cancer Phenotypes via Metabolomics -- Circulating Tumour Cells -- Cancer Exosomes for Early Pancreatic Cancer Diagnosis and Role Metastasis -- Metabolism in Pancreatic Cancer -- Secondary Screening for Inherited Pancreatic Ductal Adenocarcinoma -- Role of Radiotherapy in Locally Advanced Pancreatic Cancer -- Evolution of Pancreatic Cancer Surgery -- Multiparameter Modalities for the Study of Patients in the Setting of Individualized Medicine -- Epigenetic Pharmacology -- Precision Medicine Based on Next Generation Sequencing and Master Controllers. 330 $aIn organizing the second edition of this renowned Handbook, Dr. Neoptolemos and his co-editors have produced and updated a revised edition to the distinguished Major Reference Work devoted to pancreatic cancer. Like its preceding edition, the second edition continues to have a widespread appeal among clinicians, pathologists and basic scientists, who are now struggling to understand this complex and rapidly expanding field. Because of the recent and vast growth in both the clinical and scientific research being done in pancreatic cancer, (there is currently an unprecedented investment by academia and industry in this field), each research?s knowledge of other specialty areas outside his or her own is often quite limited. The aim of the new edition is to place the tangible advances, including new developments in surgical approaches with regards to resection techniques, the state of laparoscopic approaches, the growing impact of surgical approaches in the management of recurrent pancreatic cancer, controversies in the management of IMPN as the precursor lesion for PDAC and others ? readily at hand. The second edition focuses on advances that will not become dated, and the editors have chosen authors, who are the very best in each area. 410 0$aSpringer reference. 606 $aCancer$xResearch 606 $aOncology 606 $aEndocrinology 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053 615 0$aCancer$xResearch. 615 0$aOncology. 615 0$aEndocrinology. 615 14$aCancer Research. 615 24$aOncology. 615 24$aEndocrinology. 676 $a616.994370072 702 $aNeoptolemos$b John P$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aUrrutia$b Raul$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aAbbruzzese$b James L$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aBüchler$b Markus W$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298417803321 996 $aPancreatic Cancer$92509315 997 $aUNINA